PODD logo

Insulet Corporation (PODD)

$145.34

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on PODD

Market cap

$10.08B

EPS

6.12

P/E ratio

25.3

Price to sales

3.07

Dividend yield

--

Beta

1.057673

Price on PODD

Previous close

$145.29

Today's open

$144.69

Day's range

$142.24 - $148.49

52 week range

$126.40 - $354.88

Profile about PODD

CEO

Ashley McEvoy

Employees

5400

Headquarters

Acton, MA

Exchange

Nasdaq Global Select

Shares outstanding

69371043

Issue type

Common Stock

PODD industries and sectors

Healthcare

Medical Equipment & Supplies

News on PODD

This Insulet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

news source

Benzinga • 5 hours ago

news preview

Insulet Corporation (PODD) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Insulet Corporation (PODD) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • 4 hours ago

news preview

Why Insulet (PODD) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

news source

Zacks Investment Research • Nov 12, 2026

news preview

Insulet (PODD) Just Overtook the 20-Day Moving Average

After reaching an important support level, Insulet (PODD) could be a good stock pick from a technical perspective. PODD surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

news source

Zacks Investment Research • Nov 12, 2026

news preview

Insulet: Rivals Are Building Patch Pumps, But Insulet Already Owns The Pharmacy Counter

Insulet is undervalued, trading at a sub-median multiple despite 20% revenue growth and expanding margins. PODD's pharmacy-based, fully disposable model and dominant new patient onboarding differentiate it from emerging tubeless competitors. Record gross margins (74.2%) and upgraded guidance—2026 revenue growth of 21%-22% and adjusted EPS growth above 30%—underscore strong operating leverage.

news source

Seeking Alpha • Nov 11, 2026

news preview

Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"

Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.

news source

Zacks Investment Research • Nov 10, 2026

news preview

For World Diabetes Day, Insulet Launches “Give Yourself the Freedom to” Campaign, Encouraging People with Diabetes to Prioritize Their Well-Being

ACTON, Mass.--(BUSINESS WIRE)--In recognition of World Diabetes Day on November 14, 2026, Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its “Give Yourself the Freedom to” campaign designed to raise awareness of the often overlooked emotional and mental demands of living with diabetes and encourage people living with diabetes to prioritize their own well-being. “Living with d.

news source

Business Wire • Nov 9, 2026

news preview

What Insulet (PODD) Said on Its Q3 Earnings Call

Insulet NASDAQ: PODD reported third-quarter revenue of $842 million, up 19.2% on a reported basis and 19.6% on a constant-currency basis, as international growth outpaced the company's plans and U.S. performance landed within its guidance range.

news source

MarketBeat • Nov 4, 2026

news preview

Insulet Corporation (PODD) Q3 2026 Earnings Call Transcript

Insulet Corporation (PODD) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 4, 2026

news preview

Insulet Reports Third Quarter 2026 Results

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2026. Third Quarter Financial Highlights: Revenue of $842.0 million, up 19.2%, or 19.6% in constant currency, slightly above the high end of the Company's guidance range of 17.5% - 19.5% at constant currency rates Total Omnipod revenue o.

news source

Business Wire • Nov 4, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Insulet Corporation

Open an M1 investment account to buy and sell Insulet Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in PODD on M1